All In Biotech

Drug Trial Radar · NCT07157033

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

A Phase 1/2a, Open Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of XER-001 (Amifostibe for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment of Locally-Advanced Pancreatic Adenocarcinoma

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Jan 1, 2026

Primary completion

Jul 31, 2029

Study completion Jul 31, 2034

Sponsor

Lead sponsor
Xerient PharmaIndustry
Sponsor type
Industry
First posted
Sep 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability and efficacy of XER-001 and identify a best dose for future studies.

Conditions

  • Locally Advanced Pancreatic Adenocarcinoma
  • Locally Advanced Pancreas Cancer
  • Locally Advanced Pancreatic Ductal Adenocarcinoma

Interventions

  • XER-001Drug

    XER-001 (Amifostine for nasoduodenal delivery)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Assessments [Dose Escalation]Time frame: 18 Months
  2. Safety Assessments [Dose Escalation]Time frame: 18 Months
  3. Safety Assessments [Dose escalation and Dose Expansion]Time frame: 40 months
  4. Safety Assessments [Dose Escalation and Dose Expansion]Time frame: 40 Months
  5. Safety Assessments [Dose Escalation and Dose Expansion]Time frame: 40 Months
  6. Safety Assessments [Dose Escalation and Dose Expansion]Time frame: 40 Months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • CIty of Hope

    Irvine, California · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Christus St. Vincent Regional Cancer Center

    Santa Fe, New Mexico · Recruiting

  • Oncology Consultants, P.A.

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.